Home
Storia in 1 fonti
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for schizophrenia drug.
Raccontata da
endpoints.news
Timeline cronologica
- ·
Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3
Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's fadeucravacitinib hits Phase 3 endpoint in psoriasis.
- ·
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for schizophrenia drug.